MedTrace Logo

CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease

NCT07305116 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2026-02-03

No results posted yet for this study

Summary

CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B cell mediated autoimmune disease.

Conditions

  • Autoimmune Diseases
  • Systemic Lupus Erthematosus (SLE)
  • Multi-Drug Resistant Nephrotic Syndrome
  • IgA Nephropathy (IgAN)
  • Systemic Sclerosis (SSc)
  • ANCA Associated Systemic Vasculitis

Interventions

BIOLOGICAL

UCAR T-cell

Universal allogeneic anti-CD19/BCMA CAR T-cells.

Sponsors & Collaborators

  • The Children's Hospital of Zhejiang University School of Medicine

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
3 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-01
Primary Completion
2028-12-31
Completion
2029-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07305116 on ClinicalTrials.gov